<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38145749</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-7184</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><PubDate><Year>2024</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Metabolic engineering</Title><ISOAbbreviation>Metab Eng</ISOAbbreviation></Journal><ArticleTitle>Selective microbial production of lacto-N-fucopentaose I in Escherichia coli using engineered α-1,2-fucosyltransferases.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>11</EndPage><MedlinePgn>1-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ymben.2023.12.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1096-7176(23)00182-9</ELocationID><Abstract><AbstractText>Lacto-N-fucopentaose I (LNFP I) is the second most abundant fucosylated human milk oligosaccharide (HMO) in breast milk after 2'-fucosyllactose (2'-FL). Studies have reported that LNFP I exhibits antimicrobial activity against group B Streptococcus and antiviral effects against Enterovirus and Norovirus. Microbial production of HMOs by engineered Escherichia coli is an attractive, low-cost process, but few studies have investigated production of long-chain HMOs, including the pentasaccharide LNFP I. LNFP I is synthesized by α1,2-fucosyltransfer reaction to the N-acetylglucosamine moiety of the lacto-N-tetraose skeleton, which is catalyzed by α1,2-fucosyltransferase (α1,2-FucT). However, α1,2-FucTs competitively transfer fucose to lactose, resulting in formation of the byproduct 2'-FL. In this study, we constructed LNFP I-producing strains of E. coli with various α1,2-fucTs, and observed undesired 2'-FL accumulation during fed-batch fermentation, although, in test tube assays, some strains produced LNFP I without 2'-FL. We hypothesized that promiscuous substrate selectivity of α1,2-FucT was responsible for 2'-FL production. Therefore, to decrease the formation of byproduct 2'-FL, we designed 15 variants of FsFucT from Francisella sp. FSC1006 by rational and semi-rational design approaches. Five of these variants of FsFucT surpassed a twofold reduction in 2'-FL production compared with wild-type FsFucT while maintaining comparable levels of LNFP I production. These designs encompassed substitutions in either a loop region of the enzyme (residues 154-171), or in specific residues (Q7, H162, and L164) that influence substrate binding either directly or indirectly. In particular, the E. coli strain that expressed FsFucT_S3 variants, with a substituted loop region (residues 154-171) forming an α-helix structure, achieved an accumulation of 19.6 g/L of LNFP I and 0.04 g/L of 2'-FL, while the E. coli strain expressing the wild-type FsFucT accumulated 12.2 g/L of LNFP I and 5.85 g/L of 2'-FL during Fed-bach fermentation. Therefore, we have successfully demonstrated the selective and efficient production of the pentasaccharide LNFP I without the byproduct 2'-FL by combining protein engineering of α1,2-FucT designed through in silico structural modeling of an α1,2-FucT and docking simulation with various ligands, with metabolic engineering of the host cell.</AbstractText><CopyrightInformation>Copyright © 2023 International Metabolic Engineering Society. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Endo</LastName><ForeName>Shun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Kirin Central Research Institute, Kirin Holdings Company, Limited, 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugita</LastName><ForeName>Tomotoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Kirin Central Research Institute, Kirin Holdings Company, Limited, 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamai</LastName><ForeName>Sayaka</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Kirin Central Research Institute, Kirin Holdings Company, Limited, 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Kirin Central Research Institute, Kirin Holdings Company, Limited, 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamazaki</LastName><ForeName>Fuhito</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Kirin Central Research Institute, Kirin Holdings Company, Limited, 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampei</LastName><ForeName>Sotaro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Kirin Central Research Institute, Kirin Holdings Company, Limited, 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snarskis</LastName><ForeName>Gustautas</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biomatter, Žirmūnų G. 139A, Vilnius 09120, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valančiūtė</LastName><ForeName>Audronė</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomatter, Žirmūnų G. 139A, Vilnius 09120, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazemi</LastName><ForeName>Masoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomatter, Žirmūnų G. 139A, Vilnius 09120, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rokaitis</LastName><ForeName>Irmantas</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Biomatter, Žirmūnų G. 139A, Vilnius 09120, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koketsu</LastName><ForeName>Kento</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Kirin Central Research Institute, Kirin Holdings Company, Limited, 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: Kento_Kouketsu@kirin.co.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Belgium</Country><MedlineTA>Metab Eng</MedlineTA><NlmUniqueID>9815657</NlmUniqueID><ISSNLinking>1096-7176</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7578-25-8</RegistryNumber><NameOfSubstance UI="C045442">lacto-N-fucopentaose I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009844">Oligosaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.-</RegistryNumber><NameOfSubstance UI="D005647">Fucosyltransferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="Y">Escherichia coli</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008895" MajorTopicYN="Y">Milk, Human</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009844" MajorTopicYN="N">Oligosaccharides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005647" MajorTopicYN="N">Fucosyltransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enzyme engineering</Keyword><Keyword MajorTopicYN="N">Human milk oligosaccharide</Keyword><Keyword MajorTopicYN="N">Lacto-N-Fucopentaose</Keyword><Keyword MajorTopicYN="N">Microbial production</Keyword><Keyword MajorTopicYN="N">α-1,2-fucosyltransferase</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>25</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38145749</ArticleId><ArticleId IdType="doi">10.1016/j.ymben.2023.12.009</ArticleId><ArticleId IdType="pii">S1096-7176(23)00182-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle>